Announcement of providing guarantee for the holding company
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2019-010
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
Providing Guarantee for Holding Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Tips
● Names of Guarantees: Zhejiang Jianfeng Pharmaceutical Co., Ltd., Shanghai Beika Pharmaceutical Technology Co., Ltd. and its wholly-owned subsidiaries, Guizhou Huangpinggu Longmingchuan Cement Co., Ltd., Zhejiang Jianfeng International Trade Co., Ltd.
● To set up a financing guarantee amount: Set up a financing guarantee amount 8.8 .3 billion yuan.
● Is there any counter-guarantee in this guarantee: No
● Cumulative quantity of overdue external guarantee: No
Overview of 1. guarantee
2019 4 26 , zhejiang Jianfeng Group Co., Ltd. held thethnd meeting of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting on his behalf and vote , complies with the relevant provisions of the "Company Law" and the company's "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the "Proposal on Providing Guarantees to Holding Subsidiaries" was deliberated and passed with 9 votes in favor, 0 votes against, and 0 abstentions.
The motion needs to be submitted to the shareholders' meeting for consideration.
Basic Information of Guaranteed 2.
1 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), registered capital 19853 Yuan, of which: the company accounts for 99.16% , registered address: on the second floor of No. 87 X02 office quality inspection building, No. 85 58 , Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province, is mainly engaged in drug research and development and production (operated with valid licenses); Import raw and auxiliary materials for production and scientific research; Imported mechanical equipment, instruments and spare parts.
, Shanghai Beika Medical Technology Co., Ltd. (hereinafter referred to as "Shanghai Beika"), with a registered capital of 2275.93 yuan, of which: the company accounts for 61.48% , registered address: Building 99 21 , 3802 , Shengang Road, Songjiang District, Shanghai, mainly engaged in: technology development, technical consultation, technical service and technology transfer in the field of medicine and chemistry; wholesale and retail of mechanical equipment, instruments and meters, edible agricultural products (excluding pig products), chemical fertilizers, feed additives, chemical raw materials and products (except dangerous goods); development and sales of pharmaceutical intermediates; import and export of goods and technologies. Shanghai Beika has three wholly-owned subsidiaries: Anhui Xinbeika Chemical Co., Ltd., Anhui Jianfeng Beika Pharmaceutical Co., Ltd., and Anhui Zhongwang Pharmaceutical Co., Ltd. 3
5000 .06 million yuan, the company accounts for 100% , registered address: Gulong Industrial Park, Huangping County, Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou Province, mainly engaged in research and development, production and sales of cement products and process equipment; ordinary Portland cement and commercial concrete, cement products, limestone, artificial sand, gravel, aggregate manufacturing sales. 4
3000 .14 million yuan, of which: the company accounts for 93.33% , Jianfeng Pharmaceutical accounts for 6.67 , registered address: No. 88 , No. 119, changchun West Road, Jindong Economic Development Zone, Zhejiang, mainly engaged in: import and export of goods and technologies permitted by national laws and regulations without pre-approval; road cargo transportation; road transport station (field) operation; food management; sales of pharmaceutical intermediates, pharmaceutical equipment, etc. and online sales; national laws and policies permit Business consulting service activities; carry out international transportation agency business for import and export goods, and general cargo storage services. 3. of the above subsidiaries 2018
financial data (unit: ten thousand yuan)
|
# total 144 liabilities
|
total current liabilities
|
total bank loans
|
net assets
|
Total Operating Income
|
Net Profit Attributed to Owners of Parent Company
|
| Peak Pharmaceutical
144410.77
|
94187.16
|
88383.69
|
4600
|
50223.61
|
148762.44
|
3696.70
|
| Shanghai North Carolina
24853.30
|
10729.36
|
10685.21
|
3700
|
14123.94
|
21469.79
|
-90.77
|
| Peak International Trade
13677.85
|
11564.77
|
11462.27
|
|
2113.08 |
14443.11
|
567.82
|
| Mingchuan, Guizhou
6955.58
|
7633.27
|
7633.27
|
|
-677.70 |
0
|
-240.56
|
|
, the guarantee provided by the holding subsidiary to borrow money from financial institutions, set the following limits:
Limit (RMB 10,000)
|
| Zhejiang Jianfeng Pharmaceutical Co., Ltd.
30000
|
| Shanghai Beika Pharmaceutical technology Co., Ltd. and its wholly-owned subsidiary
20000
|
| Guizhou Huangpinggu Longmingchuan Cement Co., Ltd.
30000
|
| Zhejiang Jianfeng International Trade Co., Ltd.
8000
|
|
More information
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-22
Peak International Trade was rated as "excellent delivery warehouse" by the big business"
On April 12, the 2019 Dalian Commodity Exchange Industrial Products Delivery Work Summary Meeting was held in Dalian. Jianfeng International Trading Company was rated as "2018 (Industrial Products) Excellent Delivery Warehouse" and Ruan Weihang, an employee of the International Trading Company, was rated as "2018 (Industrial Products) Excellent Futures Specialist in Designated Delivery Warehouse". The delivery link is the bridge link between the futures and cash markets, an important area of risk prevention and control in the futures market, and a strong guarantee for the smooth operation and function of the market. Since obtaining the qualification of PVC delivery warehouse in 2009, the chemical warehousing and logistics business of international trading company has developed steadily. In terms of management, the international trading company strictly follows the various systems of the Dalian Commodity Exchange to implement warehouse-in and warehouse-in management. The management level has been improved year by year. Broken packages have been handled on the spot, and the loss of goods has been greatly reduced. The management goal of daily clearing has been achieved, and standardized operations have been achieved; in terms of business marketing, the futures business has driven the gradual development and growth of the spot business, futures varieties have developed from a single PVC variety to four varieties of PVC, PP, PE and plywood. The business volume has increased year by year and has exceeded 500000 tons. The operation volume can exceed 2500 tons/day; In terms of customer service, from zero experience in futures business to now, customer reputation has increased year by year, and customer complaints have gradually decreased. The annual excellent delivery warehouse of the judges is the full affirmation of Dalian Commodity Exchange on the functions of international trading companies, market satisfaction, futures management level and standardization of warehouse daily management. Lou Chunming, general manager of the international trading company, said that the international trading company will implement
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-30
Peak Cement Won the Bid for National Key Project Daye Peak Becomes Huang-Huang Railway Supplier
On March 19, Daye Jianfeng Cement Company officially received a notice from China Railway Construction Material Collection Center that the company was shortlisted for the new Huang (Mei) Huang (Zhou) railway project in the Hubei section of the Shanghai-Chengdu high-speed railway along the Yangtze River in the second place, and obtained the right to supply the 6th package of cement. This is the first stick undertaken by Daye Jianfeng in 2019, and it is also the second time to enter the high-speed rail project after the Wu (Han) Jiu (Jiang) high-speed rail. The Huanghuang high-speed railway is a component of the "eight vertical and eight horizontal" high-speed railway network in the "National Medium and Long-term Railway Network Plan". It is a component of the Wuhan-Hangzhou and Beijing-Hong Kong-Kowloon high-speed railway network. It has a total length of 125 kilometers and a design speed of 350 kilometers per hour. It will start construction at the end of 2018. It will be opened to traffic in 2021. In addition to the characteristics of large demand for high-speed railway and highway projects, the project time span is long and the product quality requirements are high, especially the high-speed railway project has extremely strict requirements on the alkali content of cement. After participating in the bidding, Yuan Xianming, executive deputy general manager of Daye Peak, organized production, quality control, procurement and other relevant departments for many times to carry out tests on the production of low-alkali cement and adjust the proportion of raw materials. The quality control department also sent samples to the provincial professional inspection department for comparative inspection to ensure product stability. The marketing department carefully checked the details of the tender, strictly checked and repeatedly deduced the bid price. Finally, with the full cooperation of all departments, the successful bidding was passed, finalist Huang-Huang high-speed rail project. It is understood that as the country continues to increase investment in infrastructure transportation construction, daye peak adjusted its work direction at the end of 2018, requiring marketing work in 2019 to focus on key projects.
2020
07-31
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-22
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-31